Diagnosis type
Pathology should clarify adenocarcinoma or another pancreatic tumor type, and whether tissue confirmation exists.
A careful file review for pancreatic cancer, focused on histology, stage, biliary status, nutrition, pain, CA 19-9 trend, prior systemic therapy and whether the patient is stable enough for international coordination.
Pancreatic cancer evaluation depends heavily on stage, vascular involvement, metastatic spread, liver function and the patient’s physical reserve. The same diagnosis can mean very different things for a patient after surgery, during chemotherapy or after progression.
The coordination goal is to convert scattered reports into a concise medical file that shows what is confirmed, what is urgent and what question should be sent to the specialist.
Pathology should clarify adenocarcinoma or another pancreatic tumor type, and whether tissue confirmation exists.
CT/MRI/PET reports should describe pancreas location, vascular involvement, liver/peritoneal spread and surgical opinion if available.
Jaundice, stent placement, bilirubin trend, cholangitis and liver enzymes affect safety and timing.
FOLFIRINOX, gemcitabine-based therapy, radiation, surgery and response/progression dates are summarized.
Weight loss, appetite, pancreatic enzyme use, pain control and performance status are documented.
Second opinion, post-progression review, supportive care planning or Cuba-based discussion must be defined.
Each item below affects how the file is interpreted, what the physician can answer and whether additional documents are needed before a responsible response.
Resectable, borderline, locally advanced and metastatic contexts are reviewed differently.
Biliary obstruction or cholangitis can make international travel unsafe until controlled.
Neuropathy, blood counts, kidney/liver function and weight loss affect next-step suitability.
CA 19-9 trend is interpreted only with clinical and imaging context, not as a standalone decision.
Most delays happen when the diagnosis is described verbally but the file lacks dates, reports, imaging, pathology or the current specialist recommendation. The documents below are requested before the file is considered ready for review.
The page does not present a hospital visit or travel plan as automatically suitable. Any Cuba-related discussion remains conditional on physician review of the current file.
Jaundice, infection and severe nutritional decline are addressed locally before any travel discussion.
The file determines whether a specialist opinion is meaningful before logistics or payment planning.
Pain, nutrition, fatigue and family goals are included because they affect realistic coordination.
Timing is critical here; the review process must not delay treatment already under way.
Nimotuzumab (CIMAher) has been studied in pancreatic cancer, including in combination with gemcitabine. Results suggest a signal in certain subgroups but are not at a level that changes international standard care. Any such option can only be considered after oncology review, and alongside rather than instead of a standard chemotherapy plan.
The most decisive distinction in pancreatic cancer is whether the tumour is resectable, borderline resectable or unresectable. That can only be established with a pancreas-protocol CT and assessment of the relationship to major vessels. In a patient who still has a surgical option, delay can remove it.
Jaundice from biliary obstruction, uncontrolled pain, weight loss and a tendency to clotting are common in this diagnosis. Managing them comes before travel planning. Current performance status determines whether a long flight and a change of programme are appropriate at all.
Without a pancreas-protocol CT and vessel-involvement detail, no opinion on surgical candidacy can be given.
Biliary drainage and effective analgesia are items to resolve before, not after, an international review.
Weeks matter here; stopping current treatment while waiting for an international opinion is not advised.
International coordination should never delay emergency care. If any of the following are present, the patient should be assessed locally first.
No. It explains how the file is organized for review. Suitability, route, timing and safety can only be determined by physicians after reviewing the complete current record.
A summary helps, but it is not enough for most oncology reviews. Pathology, imaging, treatment history, lab results and the latest oncology note are usually needed.
No. Cuba Health Assist coordinates records, communication, translation support and logistics. Medical decisions remain with licensed physicians and the patient’s treating team.
The team will request missing reports before presenting the case as ready. This protects the patient from receiving a weak or unrealistic response.
No. Severe or rapidly worsening symptoms require local emergency or oncology care first. International coordination is not an emergency service.
A coordinator will organize the medical information and guide the next step according to specialist review. The process is designed to be transparent, clinically cautious and written.